Application of ginkgolide in preparation of medicine for preventing and/or treating Guillain-Barre syndrome
阅读说明：本技术 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途 (Application of ginkgolide in preparation of medicine for preventing and/or treating Guillain-Barre syndrome ) 是由 李慧琴 唐永鑫 刘科 于 2019-11-25 设计创作，主要内容包括：本发明涉及医药技术领域,具体公开了一种银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途。本发明公开了银杏萜内酯具有一定减轻EAN小鼠病情的作用,并且不同的银杏萜内酯单体化合物组合使用显示出一定的协同增效作用。本发明公开了银杏萜内酯在临床上可用于预防和/或治疗吉兰-巴雷综合征的症状,且未观察到任何不良反应。本发明所提供的药物原料获取方式普遍,制备成本更低,病患治疗成本低,安全性强。(The invention relates to the technical field of medicines, and particularly discloses application of ginkgolide in preparation of a medicine for preventing and/or treating Guillain-Barre syndrome. The invention discloses that ginkgolide has a certain effect of relieving the condition of an EAN mouse, and different ginkgolide monomer compounds are combined to show a certain synergistic effect. The invention discloses that ginkgolide can be clinically used for preventing and/or treating symptoms of Guillain-Barre syndrome without any adverse reaction. The medicine provided by the invention has the advantages of universal raw material acquisition mode, lower preparation cost, low treatment cost of patients and strong safety.)
1. Use of a ginkgolide or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, or any crystal form, racemate, metabolite thereof, or a mixture thereof in the preparation of a medicament for preventing and/or treating Guillain-Barre syndrome.
2. Use according to claim 1, wherein the ginkgolide is a ginkgolide or/and a ginkgolide.
3. The use of claim 2, wherein the ginkgolide is one or more of ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide M, ginkgolide J, ginkgolide K, ginkgolide L, ginkgolide N, ginkgolide P, ginkgolide Q, bilobalide.
4. The use of claim 3, wherein the ginkgolides are bilobalide: ginkgolide B ═ 35-60 to (40-65) w/w; or the ginkgolide A and the ginkgolide C are (40-75) to (25-60) w/w; or the ginkgolide M and the ginkgolide K are (30-60) to (40-70) w/w; or bilobalide A, bilobalide B and bilobalide C in the ratio of 1 to 1 (w/w/w); or one of ginkgolide A, ginkgolide B, ginkgolide C, bilobalide (w/w/w/w) 12:34:6: 48.
5. The use of claim 3, wherein the ginkgolides are ginkgolide A, ginkgolide B, ginkgolide C and bilobalide (10-35), 20-38, 5-14, 26-50) w/w/w/w.
6. Use according to claim 3, wherein the ginkgolide is selected from the group consisting of bilobalide: ginkgolide B ═ 50:50 (w/w); or bilobalide A and bilobalide C at a ratio of 50:50 (w/w); or bilobalide M and bilobalide K are 50:50 (w/w).
7. The use according to any one of claims 1 to 6, wherein the disease subtype of Guillain-Barre syndrome is acute inflammatory demyelinating polyneuropathy, acute motor axonopathy, acute motor sensory axonopathy, Mullerian snow syndrome, acute pan-autonomic neuropathy, and acute sensory neuropathy.
8. The agent for the prophylaxis and/or treatment of Guillain-Barre syndrome according to any one of claims 1 to 6, wherein the agent comprises a ginkgolide as an active ingredient, and a pharmaceutically acceptable carrier; the ginkgolide is ginkgolide B which is 35-60 w/w to 40-65 w/w; or the ginkgolide A and the ginkgolide C are (40-75) to (25-60) w/w; or the ginkgolide M and the ginkgolide K are (30-60) to (40-70) w/w; or bilobalide A, bilobalide B and bilobalide C in the ratio of 1 to 1 (w/w/w); or one of ginkgolide A, ginkgolide B, ginkgolide C, bilobalide (w/w/w/w) 12:34:6: 48.
9. The medicament of claim 8, wherein the carrier comprises one or more of a filler, a diluent, a lubricant, a glidant, an anti-adherent, a dispersant, a wetting agent, a binder, a regulator, a solubilizer, an antioxidant, a bacteriostatic agent, an emulsifier, and a disintegrant; the binder comprises one or more of acacia, gelatin, sorbitol, tragacanth, cellulose, microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose, hydroxypropyl methylcellulose, syrup, starch slurry, and polyvinylpyrrolidone; the filler comprises one or more of lactose, sugar powder, dextrin, starch and derivatives thereof, cellulose and derivatives thereof, inorganic calcium salt, sorbitol and glycine; the lubricant comprises one or more of superfine silica gel powder, magnesium stearate, talcum powder, aluminum hydroxide, boric acid, hydrogenated vegetable oil and polyethylene glycol; the disintegrating agent comprises one or more of starch and derivatives thereof, polyvinylpyrrolidone and microcrystalline cellulose; the wetting agent comprises one or more of sodium dodecyl sulfate, water and alcohol; the antioxidant comprises one or more of sodium sulfite, sodium bisulfite, sodium pyrosulfite and dibutylbenzoic acid; the regulator comprises one or more of hydrochloric acid, citric acid, potassium hydroxide, sodium citrate and buffer; the emulsifier comprises one or more of polysorbate-80, sorbitan fatty acid, pluronic F-68, lecithin and soybean lecithin; the solubilizer comprises one or more of tween-80, bile and glycerol.
10. A method of preventing and/or treating Guillain-Barre syndrome comprising administering to a subject a therapeutically effective amount of a ginkgolide, said ginkgolide being as defined in any one of claims 1 to 6.
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of ginkgolide in preparation of a medicine for preventing and/or treating Guillain-Barre syndrome.
Background
Guillain-Barre syndrome (GBS) is an immune-mediated disease that mainly affects the peripheral nervous system, is currently believed to be triggered by a variety of infectious and non-infectious factors, and is one of the common causes of acute quadriplegia.
It is currently believed that GBS is primarily an aberrant immune response triggered by infectious pathogens, involving cellular and humoral immunity. Cellular immunity: circulating T cells are activated by unknown antigens by Antigen Presenting Cells (APCs) via Major Histocompatibility Complex (MHC), T Cell Receptor (TCR) and costimulatory signals; these activated neurogenic T cells proliferate and differentiate into Th1, Th2 and Th17 and secreted immune inflammatory factors reach the peripheral nervous system through the damaged Blood Nerve Barrier (BNB); th1 mainly secretes TNF-alpha and IFN-gamma to activate macrophage; macrophage secretes NO, MMP and TNF-alpha, which can not only damage nerve myelin sheath and BNB, but also promote the proliferation of Th 1; th2 mainly secretes IL-4 and 6, and promotes B lymphocyte activation to cause humoral immunity; th17 secretes mainly IL-17 and IL-22, which can aggravate BNB injury and peripheral neuritis. Humoral immunity: b lymphocytes are activated by unknown antigens through APCs and are converted into plasma cells to secrete antibodies, and the activated B cells, the antibodies and the like reach the peripheral nervous system through damaged BNBs; these antibodies activate macrophages and induce antibody-mediated cytotoxicity (ADCC); can also activate complement system to form membrane attack complex; ultimately leading to damage to nerve axons and myelin sheaths.
As early as 1985, clinical studies demonstrated the role of PE (plasmapheresis) in GBS therapy, especially in patients who cannot walk within 2 weeks of onset, PE therapy can accelerate patient recovery; in 1992, randomized trials demonstrated that IVIG (intravenous immunoglobulin) was effective for GBS treatment; in 1993, glucocorticoids were not effective for GBS treatment, IVIG + PE was not superior to IVIG alone for GBS treatment in 1997; in 2004, IVIG + hormone was not superior to IVIG alone for GBS treatment; in 2016, new zealand SID-GBS studied whether poor-prognosis GBS could benefit from re-application of IVIG, also included in the international Guillain-barre Syndrome export Study multicenter Study, expecting results to be published; in 2017, a small-scale clinical trial of complement inhibitor (eculizumab) treatment for GBS phase 2 multicenter randomized clinical trial began, expecting study results.
Currently, effective immunotherapy for GBS is known for both PE and IVIG, where PE can remove large molecular particles from plasma, including cytokines, immune complexes and other inflammatory substances, but it may cause blood pressure changes, arrhythmias, use of central catheters and hemorrhage and may be associated with sepsis; IVIG can restore some patients from acute phase, reducing mortality; however, there are also a variety of side effects of intravenous gamma globulin, and a long-term follow-up shows that some patients still have neurological dysfunction in different degrees, so further exploring a new GBS treatment method remains a problem to be solved urgently in neurology.
Ginkgolide is a medicinal component in folium Ginkgo extract, and has antiallergic, antiinflammatory, antishock, ischemic injury protecting, and organ transplant rejection protecting effects (Ginkly Ju. ginkgolide pharmacological action research progress, 1995 Vol. 22, No. 3). Xujiang Ping et al reported that ginkgolides could reduce the cerebral vascular resistance of anesthetized dogs and increase cerebral blood flow, but did not affect heart rate and blood pressure (Xujiang Ping et al. the influence of ginkgolides on cerebral blood flow of dogs, J.W.Med.J.2005-01-15). At present, no report on the use of ginkgolide or ginkgo biloba extract for preventing and/or treating Guillain-Barre syndrome is seen.
Disclosure of Invention
The invention provides a new application of ginkgolide, namely an application of ginkgolide in preparing a medicament for preventing and/or treating Guillain-Barre syndrome.
Use of a ginkgolide or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, or any crystal form, racemate, metabolite thereof, or a mixture thereof in the preparation of a medicament for preventing and/or treating Guillain-Barre syndrome. As shown in the test example 1 of the invention, the inventor researches whether the ginkgolide can treat the Guillain-Barre syndrome by researching EAN (experimental autoimmune neuritis) model rat neurological symptom scores before and after the administration of the ginkgolide, and the EAN model is an ideal Guillain-Barre syndrome animal model recognized in the current medical field and has important significance in the clinical neuroimmunology research. According to the test 1, the ginkgolide can obviously reduce the clinical symptom score of rats and obviously improve the EAN epidemic situation of the rats.
Preferably, the ginkgolide is a ginkgosesquiterpene lactone or/and a ginkgolide.
Preferably, the ginkgolide is one or two or more of ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide M, ginkgolide J, ginkgolide K, ginkgolide L, ginkgolide N, ginkgolide P, ginkgolide Q and bilobalide.
Preferably, the ginkgolide is bilobalide, ginkgolide B is (35-60) to (40-65) w/w; or the ginkgolide A and the ginkgolide C are (40-75) to (25-60) w/w; or the ginkgolide M and the ginkgolide K are (30-60) to (40-70) w/w; or bilobalide A, bilobalide B and bilobalide C in the ratio of 1 to 1 (w/w/w); or one of ginkgolide A, ginkgolide B, ginkgolide C, bilobalide (w/w/w/w) 12:34:6: 48.
Preferably, the ginkgolide is ginkgolide A, ginkgolide B, ginkgolide C and bilobalide which are 10-35 w/w/w: 20-38 w: 5-14 w: 26-50 w/w/w.
Preferably, the ginkgolide is selected from bilobalide: ginkgolide B ═ 50:50 (w/w); or bilobalide A and bilobalide C at a ratio of 50:50 (w/w); or bilobalide M and bilobalide K are 50:50 (w/w).
The inventor researches and discovers that the combination of the ginkgolide monomer compound or a plurality of ginkgolide compounds can reduce the neurological symptom score of rats and improve the epidemic situation of EAN rats. In addition, in the combined use of various ginkgolide compounds, the inventor also finds that under the proportion, the combined use of the medicines can not only treat epidemic situation of an EAN rat, but also obtain curative effect which is superior to that of the original single use of any ginkgolide compound, and obtain synergistic effect.
Preferably, the disease subtypes of gillandet's syndrome are acute inflammatory demyelinating polyneuropathy, acute motor axis soviet neuropathy, acute motor sensory axis soviet neuropathy, miller-fischer syndrome, acute pan-autonomy neuropathy, and acute sensory neuropathy.
The invention also provides a medicine for preventing and/or treating Guillain-Barre syndrome, which comprises ginkgolides serving as an active ingredient and a pharmaceutically acceptable carrier, wherein the ginkgolides are bilobalide, ginkgolide B (35-60) to (40-65) w/w; or the ginkgolide A and the ginkgolide C are (40-75) to (25-60) w/w; or the ginkgolide M and the ginkgolide K are (30-60) to (40-70) w/w; or bilobalide A, bilobalide B and bilobalide C in the ratio of 1 to 1 (w/w/w); or one of ginkgolide A, ginkgolide B, ginkgolide C, bilobalide (w/w/w/w) 12:34:6: 48.
Preferably, the carrier comprises one or more of a filler, a diluent, a lubricant, a glidant, an anti-adhesion agent, a dispersing agent, a wetting agent, a binder, a regulator, a solubilizer, an antioxidant, a bacteriostatic agent, an emulsifier and a disintegrant; the binder comprises one or more of acacia, gelatin, sorbitol, tragacanth, cellulose, microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose, hydroxypropyl methylcellulose, syrup, starch slurry, and polyvinylpyrrolidone; the filler comprises one or more of lactose, sugar powder, dextrin, starch and derivatives thereof, cellulose and derivatives thereof, inorganic calcium salt, sorbitol and glycine; the lubricant comprises one or more of superfine silica gel powder, magnesium stearate, talcum powder, aluminum hydroxide, boric acid, hydrogenated vegetable oil and polyethylene glycol; the disintegrating agent comprises one or more of starch and derivatives thereof, polyvinylpyrrolidone and microcrystalline cellulose; the wetting agent comprises one or more of sodium dodecyl sulfate, water and alcohol; the antioxidant comprises one or more of sodium sulfite, sodium bisulfite, sodium pyrosulfite and dibutylbenzoic acid; the regulator comprises one or more of hydrochloric acid, citric acid, potassium hydroxide, sodium citrate and buffer; the emulsifier comprises one or more of polysorbate-80, sorbitan fatty acid, pluronic F-68, lecithin and soybean lecithin; the solubilizer comprises one or more of tween-80, bile and glycerol.
The invention also provides a pharmaceutical preparation containing the above, wherein the preparation is tablet, capsule, granule, pill, injection or powder injection.
The invention also provides a method for preparing a medicament for preventing and/or treating Guillain-Barre syndrome, which comprises mixing effective amount of ginkgolide and a medicament carrier.
The present invention also provides a method for preventing and/or treating Guillain-Barre syndrome, comprising administering to a subject a therapeutically effective amount of the above-described ginkgolide.
The invention discloses that ginkgolide has the effect of relieving the condition of an EAN mouse, and different ginkgolide monomer compounds are combined to show a synergistic effect.
Compared with gamma globulin, the ginkgolide for treating the Gimbarray syndrome provided by the invention has the advantage of being more convenient to obtain, the gamma globulin is extracted from blood plasma of healthy people, the ginkgolide is extracted and purified from ginkgo leaves, the medicine source is common, the preparation cost is lower, and the ginkgolide has a wide application prospect.
Detailed Description
As used herein, the term "prevention" refers to the prevention of disease occurrence and/or the prevention of disease recurrence.
As used herein, the term "guillain-barre syndrome", which is equivalent to "guillain-barre syndrome".
As used herein, synergistic effect means that the synergistic effect is considered to be achieved when the combined effect of the two drugs is greater than the effect of the individual drugs.
The Guillain-Barre syndrome comprises the following disease subtypes: acute Inflammatory Demyelinating Polyneuropathy (AIDP), acute motor axis soxhour neuropathy (AMAN), acute motor sensory axis soxhour neuropathy (AMSAN), Miller Fisher (MFS), acute pan-autonomic neuropathy, Acute Sensory Neuropathy (ASN).
Experimental example 1 therapeutic Effect of ginkgolide on Experimental Autoimmune Neuritis (EAN) model rat
1. Materials and methods
1.1 Experimental animals
Lewis rats, 200, SPF grade (no specific pathogen), female, 42-48 days old. Purchased from Beijing Weitonglihua laboratory animal technology Co., Ltd, animal production license number: SCXK (Jing) 2016-: no. 11400700299780.
1.2 reagents and drugs
Peripheral nerve myelin antigenic peptide fragment P253-78, custom-made by Shanghai Jier biochemistry. (peptide fragment specific structure: THR GLU SER PRO PHE LYS ASN THR GLU ILE SER PHE LYS LEU GLY GLN GLU PHEGLU GLU THR THR ALA ASP ASN ARG). Freund's incomplete adjuvant, Sigma-Aldrich, Lot # SLBQ 2284V. Mycobacterium Tuberculosis, H37Ra, heat-inactivated Mycobacterium Tuberculosis dry powder, BD Difco.
1.3 grouping and Molding
The inventor of the invention has completed related exploration on the dose-effect relationship between ginkgolide and an EAN mouse model through preliminary experiments in the earlier stage, and finds that the total administration dose of ginkgolide is in the range of 0-4.5 mg/kg, the strength of the drug effect is changed along with the continuously enhanced amount of the drug dose, and when the total administration dose of ginkgolide is in the range of 4.5-15 mg/kg, the drug effect is maximum, and the strength is not changed along with the continuous amount of the drug dose, which is specifically shown in Table 1. Therefore, in the test example 1 of the present invention, the dose is set within the range of 4.5 to 15mg/kg, and the influence of the drug dose-effect relationship on the research results can be eliminated.
The experiment was set up in 20 groups of 10 animals each
Negative control group: physiological saline
Model control group: physiological saline
Bilobalide group a (group GA): 4.5mg/kg
Bilobalide group B (GB group): 4.5mg/kg
Bilobalide group C (GC group): 4.5mg/kg
Bilobalide group J (group GJ): 4.5mg/kg
Bilobalide group M (GM group): 4.5mg/kg
Bilobalide group K (GK group): 4.5mg/kg
Bilobalide group (BB group): 4.5mg/kg
Ginkgolide group i (GA: GC: 40: 60): 8.0mg/kg
Ginkgolide group ii (GA: GC: 75: 25): 6.0mg/kg
Ginkgolide group iii (GA: GC: 50): 9mg/kg
Ginkgolide IV group (GM: GK ═ 30: 70): 6.4mg/kg
Ginkgolide group v (GM: GK ═ 60: 40): 7.5mg/kg
Ginkgolide group vi (GM: GK ═ 50: 50): 9mg/kg
Ginkgolide group vii (GB: BB ═ 40: 60): 7.5mg/kg
Ginkgolide group viii (GB: BB ═ 65: 35): 6.9mg/kg
Ginkgolide IX group (GB: BB ═ 50: 50): 9mg/kg
Ginkgolide group X (GA: GB: GC ═ 1:1: 1): 13.5mg/kg
Ginkgolide group XI (GA: GB: GC: BB ═ 12:34:6: 48): 9.4mg/kg
The combined use ratio of the ginkgolide monomer compounds is the mass ratio.
The quality proportion setting principle of the two-in-two combined use of the ginkgolide monomer compounds is as follows: the inventor firstly carries out mass 1:1, the effect difference between the combined effect of the two medicines and the single effect of each component medicine is explored, and when the combined effect of the two medicines is greater than the single effect of each component medicine, the combined use of the two medicines has a synergistic effect.
When the two medicines are used in combination to have a synergistic effect, the inventor further explores the mass ratio of the two ginkgolide monomer compounds so as to research the optimal mass ratio range of the synergistic effect when the two medicines are used in combination.
The inventor further researches whether the synergistic effect can be generated by the combined use of three or four ginkgolide monomer compounds.
Gavage is performed 2 times a day. The medicine is dissolved to 5mg/ml by auxiliary materials (glycerol: ethanol is 6: 4V/V), and then the mixture is prepared into corresponding concentration by using sterilized drinking water.
Rats in the EAN model group were injected subcutaneously with 200. mu.L/mouse (100. mu.L on each side) of hind-paw pads on both sides. The inoculum of each rat contains antigenic peptide fragment P253-78200. mu.g, Freund's incomplete adjuvant 100. mu.L, H37Ra 2mg, and 0.9% sodium chloride injection 100. mu.L. The negative control group was injected with an equal volume of saline. Animals in each group began dosing on the first day after immunization for a total of 30 days.
1.4 neurological symptom score and weight Change
The observation period is the 0 th day and the 30 th day after the molding day, the observation day is represented by a D + number, D1, D2 and D3 respectively represent the first day, the second day and the third day of observation, and the following dates are similar. Rats were weighed once every two days, and all experimental animals were taken and subjected to clinical symptom scoring. Weight weighing and clinical symptom scoring were performed daily during the week of peak disease (D14-D20) in the animals. The scoring criteria were as follows: score 0, normal; 1 minute, the tail part becomes soft; 2 minutes, the tail part cannot be lifted; 3 minutes, the body position can not be corrected by self; 4 points, ataxia; 5 points, mild paralysis of hind limbs; 6 minutes, moderate paralysis of hind limbs; 7 min, severe paralysis of hind limbs; 8 points, quadriplegia; 9 points, quadriplegia; and 10 min, death.
1.5 ankle pain test
In the vicinity of the peak of disease onset in the EAN model animal, the ankle pain test was performed on the EAN model animal and the adjuvant control animal, and the hind paw was bent (dorsiflexed) in the direction of the sole of the foot by applying a force in the resting state of the rat. The test was repeated 5 times per side, each time at intervals of at least 5 s. If the rat has hoarseness or obvious foot contraction action during dorsiflexion each time, 1 point is counted, and the total point on each side is 0-5 points.
1.6 mathematical statistics
Data are mean. + -. standard deviation
2. Results of the experiment
TABLE 1 Effect of different dosages of Ginkgo terpene lactones on neurological symptoms in EAN model rats (preliminary studies-D17)
Note: p compared to model control group<0.05; compared with the low dosage of the same product,△P<0.05
TABLE 2 Effect of Ginkgo terpene lactones on neurological symptoms in EAN model rats
Note: p <0.05 compared to model control group
The results are shown in table 2, and compared with the model group, the combination of the ginkgolide monomeric compounds and the monomeric compounds, the combination of the monomeric compounds and the combination of the monomeric compounds can reduce clinical scores in different time ranges, and the differences have statistical significance. The clinical symptoms of the EAN rats can be improved by the administration groups.
TABLE 3 synergistic effect of combination of ginkgolide A and ginkgolide C
Note: compared with the single group (GA group) with better effect, # P <0.05
As shown in Table 3, the clinical scores of ginkgolide I and ginkgolide II groups at D14-20 and those of ginkgolide III group at D12-22 were lower than those of GA group having superior effect, and the difference was statistically significant. Shows that the combination of the ginkgolide A and the ginkgolide C has a synergistic effect.
TABLE 4 synergistic effect of the combination of ginkgolide M and ginkgolide K
Note: compared with the single-use group (GK group) with better effect, # P <0.05
As shown in Table 4, in this test example, the clinical scores of ginkgolide IV group and ginkgolide V group were lower in D16-19 and those of ginkgolide VI group were lower in D14-20, compared with the group of GK, which had the superior effect; the differences are statistically significant. Shows that the combination of the ginkgolide M and the ginkgolide K has a synergistic effect.
TABLE 5 synergistic effect of combination of ginkgolide B and bilobalide
Note: compared with the best effect single use group (GB group), # P < 0.05;
as shown in table 5, clinical scores were lower in the groups of ginkgolide vii, ginkgolide viii, ginkgolide ix, ginkgolide x and ginkgolide xi in the test examples at different days in the range of days 12 to 26, compared with the GB group having the most excellent effect in monomer administration; the combination of the ginkgolide B and the bilobalide has a synergistic effect; the combination of ginkgolide A, ginkgolide B, ginkgolide C and bilobalide has synergistic effect.
TABLE 6 Effect of ginkgolides on pain response in EAN model rats
Note: p <0.05 compared to model control; compared to the GA group, # P < 0.05; $ P <0.05 compared to GK group; compared to the GB group, & P <0.05
As shown in Table 6, compared with the model group, the pain scores of the administration groups are obviously increased at the eighteenth day, and the difference has statistical significance, which indicates that the administration groups of the ginkgolide can improve the pain symptoms of the EAN rats. Compared with GA or GC group, the grades of the ginkgolide I group, the ginkgolide II group and the ginkgolide III group in the test example are all increased, wherein the difference of the ginkgolide III group has statistical significance, and the synergistic effect of the ginkgolide III group is shown to be optimal. Compared with GM or GK group, grades of ginkgolide IV group, ginkgolide V group and ginkgolide VI group are all increased, wherein differences of ginkgolide VI group have statistical significance, which indicates that synergistic effect of ginkgolide VI group is best. Compared with GB or BB group, the grades of the ginkgolide VII group, the ginkgolide VIII group, the ginkgolide IX group, the ginkgolide X group and the ginkgolide XI group are all increased, wherein the differences of the ginkgolide IX group, the ginkgolide X group and the ginkgolide XI group have statistical significance. Wherein, the combination of the ginkgolide VIII group has the best synergistic effect, the combination of the ginkgolide X group has the synergistic effect, and the combination of the ginkgolide XI group has the synergistic effect.
3. Conclusion
The results of the comprehensive clinical scoring and pain scoring show that the clinical scoring and pain scoring of the EAN rat can be improved by using monomers of ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J, ginkgolide M, ginkgolide K and bilobalide, and the combination of ginkgolide A and ginkgolide C, the combination of ginkgolide M and ginkgolide K, the combination of ginkgolide B and bilobalide, the combination of ginkgolide A, ginkgolide B and ginkgolide C and the combination of ginkgolide A, ginkgolide B, ginkgolide C and bilobalide, and the combination of the medicaments has a synergistic effect.
Experimental example 2 therapeutic Effect of ginkgolide on Experimental Autoimmune Neuritis (EAN) model Rabbit
1. Materials and methods
1.1 Experimental animals
210 big-ear white rabbits, 2.0-2.4kg of male and female. Purchased from laboratory animal committee farms, Sichuan province.
1.2 reagents and drugs
Complete Freund's adjuvant, Sigma-Aldrich. Bovine sciatic nerve myelin basic protein (P2), experimental rabbit immunoglobulin. PCR primers, internal reference B-actin (GAPDH), Trizol reagent and RT-PCR kit (Dalianbao biology company); PCRmarker (Prom ega, USA).
1.3 grouping and Molding
The experiment was set up in 21 groups of 8 animals each
Negative control group: physiological saline
Model control group: physiological saline
Positive control group: rabbit immunoglobulin, 400mg/kg.d intraperitoneal injection, continuous for 5 days
The arrangement of the ginkgolide groups was the same as that in test example 1, i.e., 18 groups including ginkgolide groups a to K (GA to GK), bilobalide group (BB) and ginkgolide groups i to xi were included, and the monomer composition and ratio of ginkgolides used in each group were the same as those in test example 1, except that all ginkgolide groups were administered at the same dose of 4.5 mg/kg.
Gavage is performed 2 times a day. The medicine is dissolved to 5mg/ml by auxiliary materials (glycerol: ethanol is 6: 4V/V), and then the mixture is prepared into corresponding concentration by using sterilized drinking water.
Establishing an EAN rabbit model: taking a certain amount of bovine sciatic nerve myelin basic protein, adding equal volume of Freund's complete adjuvant, shaking up by a test tube oscillator, fully mixing the two, and injecting the mixture into the back subcutaneous part of the rabbit at multiple points. The clinical manifestations of the vaccine were observed every day on the day after immunization, and the clinical course was judged. The following symptoms are presented as criteria for successful molding: mental retardation, impaired mobility, loss of appetite, weight loss, rough tail and foot and paw skin, weakness of limbs, flaccid paralysis, heaviness of hind limbs, reduced reflexes and stress functions.
1.4 mRNA levels of TNF-alpha, IL-4, IL-10, IL-12 in Th cells of sciatic nerve tissue
After 14 days of molding, the sciatic nerve tissues of the rabbits were anesthetized and total RNA was extracted by Trizol method. And detecting by using an RT-PCR method. (GBS is an autoimmune disease of the nervous system, in which autoreactive T cells in a patient generate a cellular immune response to the myelin P2 antigen, resulting in delayed-type allergic demyelinating peripheral nerve pathological lesions. this process is mainly based on CD4+T cell-mediated, also known as primary Th cells, differentiate into Th1 and Th2 following antigenic stimulation, and Th1 cytokines (represented by TNF- α and IL-12) primarily potentiate cell-mediated immune responses, inflammatory cytokines; th2 cytokine (represented by IL-4 and IL-10) is mainly involved in antibody-mediated immune response, and has immune down-regulation and anti-inflammatory effects. In studies of GBS and EAN, an imbalance of Th1/Th2 plays an important role in disease damage. )
1.5 mathematical statistics
Data are mean. + -. standard deviation
2. Results of the experiment
TABLE 7 Effect of Ginkgo terpene lactones on Th cytokines in EAN model rabbits
Note: p <0.05 compared to model control; compared with ginkgolide A or C group, # P < 0.05; & P <0.05 compared to bilobalide J, M or group K; compared with bilobalide B or BB group, delta P is less than 0.05
The results are shown in table 7, and compared with the model group, the combination of the ginkgolide monomeric compounds and monomeric compounds, the combination of the monomeric compounds and the combination of the monomeric compounds can improve the level of the Th cell factor in the experimental examples, and the difference has statistical significance. Th1 cytokines (represented by TNF-alpha and IL-12) primarily potentiate cell-mediated immune responses, inflammatory cytokines; th2 cytokine (represented by IL-4 and IL-10) is mainly involved in antibody-mediated immune response, and has immune down-regulation and anti-inflammatory effects. The administration groups can regulate or correct unbalanced Th1/Th2 cell factor network and regulate endogenous cell factor balance, so as to control disease process and achieve therapeutic effect.
By comparing the effects of the groups, the synergistic effect is shown again when the ginkgolide A and the ginkgolide C are combined, the synergistic effect is shown when the ginkgolide M and the ginkgolide K are combined, the synergistic effect is shown when the ginkgolide B and the bilobalide are combined, the synergistic effect is shown when the ginkgolide A, the ginkgolide B, the ginkgolide C and the bilobalide are combined, and the combined effect of the monomers in the ginkgolide XI group is.